- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00308282
A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
Phase II Study of Safety and Efficacy of Intravenous LY2127399 in Patients With Rheumatoid Arthritis Treated With Methotrexate
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Bacau, Romania, 600114
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Baia Mare, Romania, 430031
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Braila, Romania, 810217
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Brasov, Romania, 500365
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Bucharest, Romania, 024092
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Cluj-Napoca, Romania, 400006
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Constanta, Romania, 900607
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Craiova, Romania, 200322
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Iasi, Romania, 707061
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Sf. Gheorghe, Romania, 520064
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Sibiu, Romania, 550245
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Targoviste, Romania, 130083
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Targu-Mures, Romania, 540136
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
Timisoara, Romania, 300002
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Male or female between the ages of 18 and 75 years
- Have given written informed consent approval
- Women must not be at risk to become pregnant during study participation
- Diagnosis of Rheumatoid Arthritis according to the 1987 revised American Rheumatism Association (ARA) criteria for the classification of RA
- Serum C-reactive protein (CRP) measurement greater than the upper limit of normal (ULN, 0.574 mg/dL), or erythrocyte sedimentation rate (ESR) ≥28 mm/hr
- Current, regular use of Methotrexate, at a stable dose
- Biologic DMARD naïve, and have had an insufficient response (in the opinion of the investigator) to an adequate therapeutic dose of at least 1 oral DMARD
Exclusion Criteria:
- Use of excluded medications (reviewed by study doctor)
- Surgical treatment of a joint with 2 months of study enrollment that is to be assessed in the study
- Are unable to ambulate; that is, confined to bed or wheelchair bound
- Have medical findings which, in the opinion of the study doctor, put participant at an unacceptable risk for participation in the study
- Have had recent or ongoing infection which, in the opinion of the study doctor put participant at an unacceptable risk for participation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: UN
|
30 mg, 60 mg or 160 mg, IV (in the vein) in weeks 0, 3 and 6.
Treatment duration: 6 weeks.
|
Comparatore placebo: B
|
IV (in vein) in weeks 0, 3 and 6.
Treatment duration: 6 weeks.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Percentage of Participants Achieving American College of Rheumatology 20% Response (ACR20) (Effectiveness of LY2127399 in Treating Rheumatoid Arthritis Using the ACR20 Scale)
Lasso di tempo: Week 16
|
ACR Responder Index is a Composite of clinical, laboratory, and functional measures of rheumatoid arthritis (RA).
ACR20 Responders: had ≥20% improvement from baseline in both tender and swollen joint counts and ≥20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), visual analog pain scale, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP).
|
Week 16
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Number of Participants With Treatment Emergent Adverse Events (TEAE) (Safety of Repeat Doses (3) of LY2127399 Through Evaluation of Laboratory Tests, Vital Signs and Electrocardiograms)
Lasso di tempo: Baseline through Study Completion (Up to 19 Months)
|
Treatment-emergent adverse events (TEAEs) were defined as those AEs with start date and time equal to or after the start of study medication infusion. In the case of a missing onset time for an AE, an AE with a start date equal to or greater than the dosing date was considered treatment-emergent. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section. All participants who received at least one dose of study drug. Due to dosing errors (a participant received 60 mg LY2127399 in the placebo group), the safety population was adjusted to account for actual treatment received. |
Baseline through Study Completion (Up to 19 Months)
|
Evaluation of the Pharmacokinetics of LY2127399: Clearance
Lasso di tempo: 2 hours pre-dose, pre-dose, 1 hour and 4 hour(s) post dose
|
Population estimate of constant clearance as determined by population PK analysis.
A 2-compartment model was used in PK modeling.
Constant clearance is the PK parameter which describes the linear elimination of LY2127399 from serum.
|
2 hours pre-dose, pre-dose, 1 hour and 4 hour(s) post dose
|
Percentage of Participants Achieving ACR 50 and ACR70
Lasso di tempo: Baseline through Week 24
|
ACR Responder Index: composite of clinical, laboratory, and functional measures of Rheumatoid Arthritis (RA).
ACR50 and ACR70 Responder: had either a ≥50% or ≥70% improvement from baseline in both tender and swollen joint counts and either a ≥50% or ≥70% improvement in at least 3 of 5 criteria: participant's (Pt's) and physician's global assessment of disease activity, HAQ-DI (measured Pts' perceived degree of difficulty performing daily activities), joint pain, and CRP (respectively).
|
Baseline through Week 24
|
Change From Baseline in the Disease Activity Score 28 Joint Count (DAS28-CRP)
Lasso di tempo: Baseline, Week 24
|
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP [milligrams per liter (mg/L)], and participant's global assessment of disease activity using visual analog scale (VAS) (participant global VAS).
DAS28-CRP=0.56*square
root (sqrt)(TJC28)+0.28*sqrt(SJC28)+0.36*natural
log(CRP+1)+0.014*participant
global VAS+0.96.
Scores ranged from 1.0-9.4,
where lower scores indicated less disease activity and remission is DAS28-CRP <2.6.
A negative change indicated an improvement.
|
Baseline, Week 24
|
European League Against Rheumatism (EULAR28) Response: Percentage of Participants With Combined Good and Moderate Responses
Lasso di tempo: Baseline, Week 24
|
EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP.
DAS28-CRP scores range from 1.0-9.4,
where lower scores indicated less disease activity.
High disease activity: DAS28-CRP >5.1, low disease activity: DAS28-CRP <3.2, and remission: DAS28-CRP <2.6.
Participants are categorized as EULAR responders or non-responders (NR) based on improvement of DAS28-CRP scores from baseline.
EULAR DAS28-CRP responder index defines a good (absolute: <3.2 or >1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2
improvement from baseline), or no response (absolute: >5.1 or <0.6 improvement from baseline).
Percentage of participants with DAS28-CRP based EULAR response =(number of participants with specific response) / (number of participants analyzed in the group) * 100.
|
Baseline, Week 24
|
Change From Baseline (CFB) in Serum Immunoglobulins IgG, IgA and IgM
Lasso di tempo: Baseline, Week 24
|
Immunoglobulins (Ig), or antibodies, are large proteins used by the immune system to identify and neutralize foreign particles such as bacteria and viruses.
Their normal blood levels indicate proper immune status.
A negative change indicates a decrease in Ig levels.
|
Baseline, Week 24
|
Change From Baseline in CD20+ B Cell Number Count
Lasso di tempo: Baseline, Week 24
|
CD20+ B-cells are a disease-related peripheral blood biomarker used to assess disease progression of Rheumatoid Arthritis (RA).
A reduction in CD20+ B-cell values may indicate an improvement in RA symptoms.
|
Baseline, Week 24
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 11055 (Identificatore di registro: DAIDS ES Registry Number)
- H9B-MC-BCDF (Altro identificatore: Eli Lilly and Company)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- Protocollo di studio
- Piano di analisi statistica (SAP)
- Relazione sullo studio clinico (CSR)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su LY2127399
-
Eli Lilly and CompanyTerminatoArtrite reumatoideArgentina, Germania, India, Corea, Repubblica di, Stati Uniti, Ungheria, Taiwan, Bulgaria, Francia, Federazione Russa, Spagna, Ucraina, Colombia, Messico, Polonia, Giappone, Croazia, Grecia, Nuova Zelanda, Romania, Sud Africa e altro ancora
-
Eli Lilly and CompanyCompletatoInsufficienza renale cronicaStati Uniti
-
Eli Lilly and CompanyTerminato
-
Eli Lilly and CompanyTerminatoArtrite reumatoideStati Uniti, Germania, Taiwan, Francia, Giappone, Messico, Polonia, Federazione Russa, Spagna, Colombia, Argentina, Grecia, Nuova Zelanda, Sud Africa, Australia, Corea, Repubblica di, Brasile, Italia, Malaysia
-
Applied Molecular EvolutionEli Lilly and CompanyCompletatoMieloma multiploStati Uniti
-
Eli Lilly and CompanyCompletatoArtrite reumatoideArgentina, India, Stati Uniti, Ungheria, Bulgaria, Messico, Ucraina, Colombia, Taiwan, Polonia, Giappone, Corea, Repubblica di, Nuova Zelanda, Romania, Sud Africa, Australia, Croazia, Lituania, Malaysia, Federazione Russa, Slovacchi... e altro ancora
-
Eli Lilly and CompanyCompletatoLupus eritematoso sistemico | Malattia autoimmune | Malattia del tessuto connettivoIndia, Stati Uniti, Ungheria, Romania, Spagna, Francia, Taiwan, Federazione Russa, Regno Unito, Australia, Lettonia, Messico, Sud Africa, Canada, Israele, Brasile, Serbia, Ecuador, Malaysia, Nuova Zelanda, Tunisia
-
Eli Lilly and CompanyCompletato
-
Eli Lilly and CompanyTerminatoLupus eritematoso sistemico | Malattia autoimmune | Malattia del tessuto connettivoStati Uniti
-
Eli Lilly and CompanyCompletatoUno studio per pazienti con artrite reumatoide attiva nonostante la terapia con metotrexato in corsoArtrite reumatoideStati Uniti, Messico, Ungheria, India, Argentina, Chile, Ucraina, Australia, Romania, Germania, Polonia, Slovacchia